Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
Public ClinicalTrials.gov record NCT02445976. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide and/or abiraterone.
Study identification
- NCT ID
- NCT02445976
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 197 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2015 (Type not available)
- Primary completion
- Dec 2018 (Actual)
- Completion
- Jan 2019 (Actual)
- Last update posted
- Feb 1, 2019
2015 – 2019
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35249 | — |
| Mayo Clinic | Scottsdale | Arizona | 85054 | — |
| University of California at Los Angeles | Los Angeles | California | 90095 | — |
| Yale University | New Haven | Connecticut | 06519 | — |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| GU Research Network | Omaha | Nebraska | 68130 | — |
| New Mexico Cancer Care Alliance | Albuquerque | New Mexico | 87106 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
| Virginia Oncology Associates | Hampton | Virginia | 23666 | — |
| University of Washington | Seattle | Washington | 98109 | — |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53715 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02445976, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2019 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02445976 live on ClinicalTrials.gov.